Skin Surgery Techniques: Excision of Basal Cell Carcinoma

Roflumilast 0.15% is the only 1 of 4 newly evaluated branded topical therapies to receive the Academy's strong recommendation for AD management in adults.

PODCAST: Listen to our first episode for new research on bacterial vaginosis, a new treatment option for chronic urticaria, and more.

Dupilumab is the first targeted treatment for B to receive FDA approval, showing improved remission rates, itch reduction, and lower steroid use in pivotal trial.

At one time or another, every primary care physician will likely see a patient who is a hypochondriac, a chronic complainer, or a substance abuser. Rather than seeing these patients as difficult and avoiding them as much as possible, the physician can reframe the problem as an opportunity for growth and development. Dr Lieberman suggests that keeping the sessions brief but allowing more frequent visits and addressing medical and psychosocial concerns will make your relationship with your patient more positive. Managing hypochondriacal patients, chronic complainers, and substance abusers will be much easier after listening to Dr Lieberman’s suggestions.

Explore key insights from the 2025 Revolutionizing Atopic Dermatitis meeting, featuring expert interviews and the latest treatment advancements.

At RAD 2025, Johann Gudjonsson, MD, PhD, discussed the OX-40 pathway’s role in AD, genetic links to disease risk, and promising combination therapies in development.